Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech LSE:HCM London Ordinary Share KYG4672N1016 ORD USD1
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +2.50p +0.07% 3,470.00p 3,435.00p 3,505.00p 3,470.00p 3,467.50p 3,467.50p 982 10:09:12
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 175.0 -38.3 16.2 224.9 2,107.51

Hutchison China Meditech Share Discussion Threads

Showing 1026 to 1050 of 1050 messages
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
DateSubjectAuthorDiscuss
23/7/2017
21:09
Yes, the CEO said in April they are working on 2 or 3 things and any one of which comes to fruition will radically alter 2017 guidance. They have major late stage assets which need to be taken global and big Pharma, some of whom are facing a patent cliff, will no doubt be looking. The CEO reiterated more than once that big deals are being looked at.
nerdofsteel
22/7/2017
09:30
Is that based on anything?
hamsterdam
22/7/2017
08:56
Big Pharma licensing deal coming I think
nerdofsteel
18/7/2017
15:57
Lots and lots of news due
nerdofsteel
17/7/2017
16:21
2 weeks today until interims
nerdofsteel
15/7/2017
07:38
Decision by Lilly not made public so I assume they have deferred for a while until they analyse the data and consider how the drug may compete with their other one
nerdofsteel
13/7/2017
08:11
We still have all this material news to come this year:- Savolitinib Phase III in c-Met-driven PRCC - will include large up-front Milestone payment $5m) - COMPLETE Epitinib Phase II/III in first-line patients with EGFR-mutant NSCLC with brain metastasis Savolitinib Phase III in combination with Tagrisso® (osimertinib) in second-line NSCLC (T790M-/c-Met+) Fruquintinib NDA in China by mid 2017 - Milestone (submitted June 12th) - COMPLETE $40m dividend due from Commercial JV by end June Savolitinib PRCC Possible U.S. NDA under BT designation in 2017 (pending FDA questions) Lilly decision by end May on whether to commercialise Fruq outside of China (decision can be delayed for a further year if they wish, but will have to pay more) - PENDING
nerdofsteel
13/7/2017
08:10
https://seekingalpha.com/article/4087275-chinese-oncology-company-great-potential?auth_param=1dk0ei:1cmclhp:1f288d3bb15c78e187ced953dcba7e21&uprof=45&dr=1 "The relative ignorance in the US about the company’s potential makes it a great investment right now" This article offers a great perspective for those looking to invest for the long term, and by that I mean 5 years + And it is the U.S share price that mainly drives the UK share price now, as volumes are usually bigger on NASDAQ
nerdofsteel
07/7/2017
08:52
Yesterdays news that BGNE (which IPO'd on NASDAQ just before us) has done a deal with Celgene demonstrates that big U.S Biopharmas are keen to do deals with late stage Biotechs like us. Watch this space for a deal here - we have 100% global rights at the moment to Sulfatinib, Epitinib and other drugs which Big Phrama are probably looking at with increasing interest. They get potential BT with these and can leverage low cost development. These assets are due for launch in the next few years and are either First or Best in Class. I think a deal similar to the Celgene-Beigene one announced yesterday is on the cards here. And I note Celgene took a direct 5.9% stake in Beigene delivering immediate Shareholder value day 1.
nerdofsteel
29/6/2017
09:59
Fantastic news today on Phase III PRCC Savolitinib This is a GLOBAL trial - extremely important and this will be pushed through very quickly The U.S market will loe this and continue to drive the price I continue to buy
nerdofsteel
29/6/2017
09:14
A nice quiet bulletin board, very few private Investors Very busy company, good newsflow.
haydock
20/6/2017
07:04
indeed! A nice quiet bulletin board, very few private Investors and the herd will hopefully never arrive because this is a very very long term investment. That said, it has and will continue to deliver very very significant value to those Shareholders who are prepared to stay invested for many years - no day traders here...
nerdofsteel
19/6/2017
09:28
Facinating: 2nd largest share on AIM, nil interest, when all systems go ! Must say something about bb's. Certainly the usual negative posters have not featured, a greatly refreshing change. Onward & upwards.
haydock
13/6/2017
07:54
From today's Times Drug development is all about pushing boundaries, and that is the case at Hutchison China Meditech, or Chi-Med, as it is known. The Shanghai-based pharmaceuticals company, whose biggest shareholder is Li Ka-shing’s CK Hutchison Group, is on the verge of launching the first mainstream drug developed in China from design to production. Fruquintinib, a potential treatment for various cancers, has been in development for about a decade. The drug passed a major milestone in March when Chi-Med unveiled positive phase III trial results for patients with advanced colorectal cancer, which was presented at the American Society of Clinical Oncology’s annual gathering in Chicago last week. Yesterday, as expected, Chi-Med submitted its application to market the drug to the China Food and Drug Administration, triggering a $4.5 million milestone payment from Eli Lilly, the US pharmaceutical group and Chi-Med’s partner on the drug. The regulatory process takes about 12 months but there are hopes Chi-Med will secure it sooner, given the attention that the drug has received and its significance to the international standing of China’s pharmaceutical industry. If Chi-Med launches the drug next year, as the market is forecasting, the opportunity is significant. Colorectal is the second most common cancer type in China, with about 380,0000 new cases a year, according to the national central cancer registry. Analysts at Stifel are pencilling in sales of $300 million to $400 million a year in China. The company also has a marketing and distribution platform which sells prescription and over-the-counter medicines and provides a launch pad to take its drug pipeline to market. Globally there are about 1.4 million new cases a year and the price would probably be higher in the US, where Chi-Med is also carrying out clinical trials and is targeting phase III results in a couple of years. With eight drug candidates in 30 clinical trials, including savolitinib, a cancer treatment being developed with Astrazeneca, the bulls have been grabbing the stock by the horns. Shares have rallied about 60 per cent over the past 12 months and remain close to March’s peak. MY ADVICE Buy WHY Shares have eased off record highs, but the pipeline is slowly delivering Here's the link to the article for those with a subscription:- hxxps://www.thetimes.co.uk/article/chi-med-on-way-to-break-out-of-china-k7x6kf9zf
nerdofsteel
12/6/2017
08:49
Our first NDA submitted - let's hope the China FDA approve in similar timescales to Icotinib (10 months) - then we will get a nice revenue and net income increase in 2018
nerdofsteel
25/5/2017
09:41
Not long now for this bit of news https://seekingalpha.com/article/4059205-lilly-faces-tricky-opt-decision-fruquintinib If Eli Lilly take up the option for global Fruquintinib, that culd/should be material to the valuation of Chi-Med when you realise forecast peak sake outside of China for all indications is $1.8bn p.a. and Chi-Med will get circa 11% of that
nerdofsteel
21/5/2017
13:34
Not long now for this bit of news https://seekingalpha.com/article/4059205-lilly-faces-tricky-opt-decision-fruquintinib If Eli Lilly take up the option for global Fruquintinib, that culd/should be material to the valuation of Chi-Med when you realise forecast peak sake outside of China for all indications is $1.8bn p.a. and Chi-Med will get circa 11% of that
nerdofsteel
23/4/2017
16:56
Seller cleared, but sector down in last few days and the election announcement caused a currency re-alignment which knocked off a few percent Lots of news due I look forward to the AGM again, on Thursday in London, where there will be a great opportunity to meet a number of key new Non Execs
nerdofsteel
19/4/2017
10:51
1. Big rise in sterling in the UK as a result of election announcement means UK shares were out of sync with US ADR price and were adjusted downwards 2. Biotech sector drop in the U.S yesterday Great opportunity to buy more shares at a cheaper price IMO
nerdofsteel
19/4/2017
10:49
Look at the charts for clues, turning down. Hopefully rounded top, after a few days.
haydock
19/4/2017
09:25
No news to support this. Only 1.72k shares traded so far today but the share price is down £1.75 = 5.76% on the FT website. Someone mentioned Tesaro and Genmab as comparators but they are down 0.09% and up 1.1% respectively so it's not a sector problem. Mm's playing games?
reptile3
19/4/2017
08:39
Any reason behind today's big drop?
hamsterdam
12/4/2017
12:38
Big Pharma is expensive but I think they will deploy any newly raised funds wisely. They have a clear vision and a strategy they are executing against. One aspect they are not too happy about is giving away rights to Savolitinib and Frquintinib a few years ago in order to raise cash for further development. If I had to guess I would say any new cash could be used to buy out Eli Lilly on Frquintinib if Lilly choose not to exercise their right to take it global. That decision has to be made any day now, or they can defer for a year and pay a higher milestone fee. Whatever happens we have a lot of news due on numerous fronts very soon and the AGM on the 27th of course. Always an interesting meeting.
nerdofsteel
12/4/2017
10:55
DBADVFN , HCM have always made it clear they will raise more cash as they progress to more phase 3 trials. They are certainly not an ordinary aim outfit. No alarms have been rung by that filing.
miti 1000
11/4/2017
14:05
All this still to come in the next few weeks and months Savolitinib Phase III in c-Met-driven PRCC - will include large up-front Milestone payment Epitinib Phase II/III in first-line patients with EGFR-mutant NSCLC with brain metastasis Savolitinib Phase III in combination with Tagrisso® (osimertinib) in second-line NSCLC (T790M-/c-Met+ Fruquintinib NDA in China by mid 2017 - Milestone due $40m dividend due from Commercial JV by end June Savolitinib PRCC Possible U.S. NDA under BT designation in 2017 Lilly decision by end May on whether to commercialise Fruquintinib outside of China (decision can be delayed for a further year if they wish, but will have to pay more)
nerdofsteel
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20170723 22:48:57